Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002262-12
    Sponsor's Protocol Code Number:DAPA-OB
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-09-01
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2019-002262-12
    A.3Full title of the trial
    "Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic
    obese patients with or without treatment with ACEIs".
    Pilot clinical trial of efficacy, low level of intervention, unicentric,
    randomized and simple blind.
    "Efecto de la dapagliflozina sobre la hiperfiltración glomerular en pacientes
    obesos sin diabetes con o sin tratamiento con IECAs".
    Ensayo clínico piloto de eficacia, de bajo nivel de intervención, unicéntrico,
    aleatorizado y simple ciego.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effect of the dapagliflozin drug on the glomerular hyperfiltration in nondiabetic
    obese patients.
    Efecto del fármaco dapagliflozina sobre la hiperfiltración glomerular en
    sujetos obesos sin diabetes.
    A.3.2Name or abbreviated title of the trial where available
    DAPA-OB
    DAPA-OB
    A.4.1Sponsor's protocol code numberDAPA-OB
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorHospital Universitari Germans Trias i Pujol
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportHospital Universitari Germans Trias i Pujol
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationHospital Universitari Germans Trias i Pujol
    B.5.2Functional name of contact pointServicio de Nefrología
    B.5.3 Address:
    B.5.3.1Street AddressCarretera de Canyet s/n,
    B.5.3.2Town/ cityBadalona
    B.5.3.3Post code08916
    B.5.3.4CountrySpain
    B.5.4Telephone number34934978865
    B.5.5Fax number34934978864
    B.5.6E-mailmarina.lmga@gmail.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Edistride
    D.2.1.1.2Name of the Marketing Authorisation holderAstraZeneca AB
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDapagliflozin
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDapagliflozin
    D.3.9.1CAS number 461432-26-8
    D.3.9.3Other descriptive nameDAPAGLIFLOZIN
    D.3.9.4EV Substance CodeSUB31650
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glomerular hyperfiltration.
    Disminución de al menos 10-20% de la tasa de filtración glomerular medida (mTFG) en pacientes obesos sin diabetes con hiperfiltración glomerular tratados con dapagliflozina 10mg.
    E.1.1.1Medical condition in easily understood language
    Treatment of glomerular hyperfiltration by the usement of dapagliflozina.
    Tratamiento de la hiperfiltración glomerular gracias al uso de dapagliflozina.
    E.1.1.2Therapeutic area Diseases [C] - Symptoms and general pathology [C23]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of dapagliflozin on mGFR in non-diabetic obese
    patients with glomerular hyperfiltration.
    El objetivo principal es evaluar el efecto sobre la mTFG de la
    dapagliflozina en pacientes obesos sin diabetes con hiperfiltración
    glomerular.
    E.2.2Secondary objectives of the trial
    Moreover, we will study the effect of dapagliflozin on blood pressure,
    weight, abdominal, proteinuria, hepatic esteatosis, aric ucid, HbA1c,
    fasting blood glycemia, insulin resistence, aldosterone, renin,
    angiotensin II and urinary biomarkers.
    Asimismo, estudiaremos el efecto de la dapagliflozina en la PA, peso,
    perímetro abdominal, proteinuria, esteatosis hepática, ácido úrico,
    HbA1c, glucemia en ayunas, resistencia a la insulina, aldosterona,
    renina, angiotensina II y biomarcadores urinarios
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1) Age ≥18 and ≤70 years
    2) Diagnosis of obesity (body mass index ≥30 Kg/m²)
    3) Diagnosis of measured glomerular hyperfiltration (mGFR ≥
    120mL/min) by clearance of iohexol.
    4) Understanding and accepting the clinical trial and willing to sign
    informed consent
    5) Twenty of the 60 subjects included must be on a stable dose of
    angiotensin converting enzyme inhibitors (ACEI) for at least 4 weeks
    prior to randomization.
    6) Women of Child-Bearing Potential (WOCBP: women who have
    experienced menarche and who have not undergone successful surgical
    sterilization -hysterectomy, bilateral tubal ligation, or bilateral
    oophorectomy- or who are not post-menopausal): must be using an
    acceptable method of contraception (barrier, hormonal or intra uterine
    device) to avoid pregnancy throughout the study and for up to 4 weeks
    after the last dose of study drug in such a manner that the risk of
    pregnancy is minimized.ç7) WOCBP must have a negative serum or urine pregnancy test result
    within 0 to 72 hours before the first dose of study drug.
    8) Women must not be breast-feeding.
    1) Pacientes de ambos sexos mayores de 18 años y menores de 70
    años.
    2) Diagnóstico de obesidad e hiperfiltración glomerular (mTFG
    >120mL/min) medido por clearance plasmático de iohexol.
    3) Comprender y aceptar los procedimientos del ensayo y firmar un
    consentimiento informado.
    4) 20 de los 60 sujetos incluídos deberán estar en tratamiento con
    IECAs a dosis estable en las últimas 4 semanas previa randomización.
    5) Las mujeres en edad fértil (no post-menopáusicas y sin esterilización
    quirúrgica –histerectomía, ligadura de trompas bilateral u ooferectomía
    biateral) deberán usa al menos un método anticonceptivo (barrera u
    hormonal) durante el ensayo y hasta 4 semanas después de la última
    dosis de dapagliflozina para minimizar el riesgo de embarazo.
    6) Las mujeres en edad fértil deberán tener una prueba de embarazo,
    sérica o urinaria, negativa entre 0 y 72h previas a la primera dosis de
    dapagliflozina.
    E.4Principal exclusion criteria
    1) Not complying inclusion criteria.
    2) Diagnosis of type 1 or type 2 Diabetes Mellitus.
    3) History of severe hypersensitivity or contraindications to
    dapagliflozin.
    4) Lactose intolerance or glucose-galactasa malabsorption.
    5) Treatment a month prior clinical trial beginning of any oral
    antidiabetic.
    6) Autosomal dominant polycystic kidney disease or autosomal recessive
    polycystic kidney disease, lupus nephritis, or ANCA-associated vasculitis.
    7) Receiving cytotoxic therapy, immunosuppressive therapy, or other
    immunotherapy for primary or secondary renal disease within 6 months
    prior to enrolment.
    8) History of organ transplantation.
    9) History of New York Heart Association (NYHA) class IV of cardiac
    insufficiency.
    10) Miocardial infarction, unstable angina, stroke or transient ischemic
    attack within 12 weeks prior to enrolment.
    11) Any medication, surgical or medical condition which might
    significantly alter the absorption, distribution, metabolism, or excretion
    of medications including, but not limited to any of the following:
    - History of active inflammatory bowel disease within the last six
    months;
    - Major gastrointestinal tract surgery such as gastrectomy,
    gastroenterostomy, or bowel resection;
    - Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding
    within last six months;
    - Pancreatic injury or pancreatitis within the last six months;
    - Evidence of hepatic disease as determined by any one of the following:
    ALT or AST values exceeding 3x ULN at the screening visit, a history of
    hepatic encephalopathy, a history of esophageal varices, or a history of
    portocaval shunt.
    12) History of drug or alcohol abuse within the 12 months prior to
    dosing, or evidence of such abuse as indicated by the laboratory assays
    conducted during the screening.
    13) Active malignancy aside from treated squamous cell or basal cell
    carcinoma of the skin.
    14) History of > 2 urinary infections within the last year.
    15) Pregnancy or breastfeeding.
    16) Participation in any clinical investigation within 3 months prior to
    initial dosing.
    17) History of noncompliance to medical regimens or unwillingness to
    comply with the study protocol.
    18) Any surgical or medical condition, which in the opinion of the
    investigator, may place the patient at higher risk from his/her
    participation in the study, or is likely to prevent the patient from
    complying with the requirements of the study or completing the study.
    19) Treatment with antidiabetic drugs, surgery, aggressive diet regimen
    or significant increase of physical exercise leading to unstable body
    weight.
    19) WOCBP who are unwilling or unable to use an acceptable method to
    avoid pregnancy for the entire study period and up to 4 weeks after the
    last dose of study drug.
    20) Iodized contrast allergy
    During the clinical trial, the treatment with concomitant non-steroidal
    anti-inflammatory drugs (NSAIDs) will be contraindicated, due to the
    risk of acute renal failure as a consequence of an excessive decrease in
    renal perfusion.
    1) No cumplir los criterios de inclusión.
    2) Diagnóstico de Diabetes Mellitus (DM) tipo 1 ó 2.
    3) Sujetos que presenten intolerancia o hipersensibilidad a la
    dapagliflozina.
    4) Sujetos que presenten intolerancia a la lactosa o malabsorción a
    glucosa-galactosa.
    5) Tratamiento un mes previo al inicio del ensayo con cualquier
    antidiabético oral.
    6) Poliquistosis renal autosómica dominante o autosómica recesiva,
    lupus eritematoso sistémico o vasculitis asociada a anticuerpos contra
    el citoplasma de los neutrófilos (ANCA).
    7) Tratamiento con terapia citotóxica, inmusupresora u otro tipo de
    inmunoterapia por enfermedad renal primaria o secundaria en los 6
    meses previos a la inclusión.
    8) Antecedente personal de trasplante renal.
    9) Antecedente de New York Heart Association (NYHA) clase IV de
    insuficiencia cardiaca.
    10) Antecedente en los últimos 12 meses de infarto agudo de miocardio,
    angina inestable, accidente cerebrovascular (ACV) o accidente
    transitorio isquémico.
    11) Cualquier medicación, situación quirúrgica o médica que podría
    alterar significativamente la absorción, distribución, metabolismo o
    excreción de medicamentos, incluyendo, pero no limitado a las
    siguientes situaciones:
    - Antecedente patológico de enfermedad inflamatoria intestinal activa
    en los últimos 6 meses.
    - Antecedente patológico de intervención quirúrgica gastrointestinal
    como gastrectomía, gastroenterostomía o resección intestinal.
    - Úlceras gastrointestinales y/o hemorragia gastrointestinal o rectal en
    los últimos 6 meses.
    - Lesión pancreática o pancreatitis en los últimos 6 meses.
    - Evidencia de hepatopatía determinada por cualquiera de las
    siguientes: antecedente patológico de hepatopatía conocida, AST y/o
    ALT >3 veces el límite superior de la normalidad en la visita de
    screening, antecedente patológico de encefalopatía hepática, varices esofágicas, shunt portocava.
    12) Antecedente personal de abuso enol u otras drogas en las últimas
    12 semanas, o evidencia de dichos abusos indicado por analítica
    sanguínea o urinaria durante el screening.
    13) Enfermedad neoplásica activa, exceptuando carcinoma escamoso o
    basocelular cutáneo.
    14) Antecedente patológico de >2 infecciones de orina en el último
    año.
    15) Mujeres embarazadas o lactantes.
    16) Participación en otro ensayo clínico en los 3 meses anteriores al
    inicio de dapagliflozina.
    17) Antecedente personal de falta de cumplimiento terapéutico o si el
    sujeto no desea cumplir el protocolo del ensayo clínico.
    18) Cualquier condición quirúrgica o médica que, de acuerdo con la
    opinión de los investigadores, podría poner al paciente en mayo riesgo al
    paciente en caso de participación en el ensayo, o es probable que evite
    que el paciente cumpla con los requisitos del estudio o lo complete.
    19) Tratamiento con medicación adelgazante, inicio de régimen dietético
    o aumento del ejercicio físico habitual que pueda alterar el peso en los 3
    meses previos al reclutamiento.
    20) Alergia al contraste yodado.
    21) Mujeres en edad fértil (no post-menopáusicas y sin esterilización
    quirúrgica –histerectomía, ligadura de trompas bilateral u ooferectomía
    bilateral) que no deseen o no puedas usar un método anticonceptivo
    (barrera u hormonal) durante todo el ensayo y hasta 4 semanas
    posteriores al a última dosis de dapagliflozina.
    Durante el ensayo clínico, se contraindicará el tratamiento con
    antiinflamatorios no esteroideos (AINEs) concomitante, ante el riesgo de
    fracaso renal agudo por excesiva disminución de la perfusión renal.
    E.5 End points
    E.5.1Primary end point(s)
    Decrease in at least 10-20% of measured glomerular filtration rate
    (mGFR) in non-diabetic obese patients with glomerular hyperfiltration
    after treatment with dapagliflozin 10mg for 6 weeks relative to placebo
    (Time Frame: week 0, 6).
    Disminución de al menos 10-20% de la tasa de filtración glomerular
    medida (mTFG) en pacientes obesos sin diabetes con hiperfiltración
    glomerular tratados con dapagliflozina 10mg (intervalo semana 0, 6).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Follow-up of 6 weeks.
    Seguimiento durante 6 semanas.
    E.5.2Secondary end point(s)
    - Maintenance of the decrease in mGFR after 24 weeks of treatment with
    dapagliflozin.
    - Comparison of the effect over mGFR between treatment with
    dapagliflozin 10mg, dapagliflozin 10mg + angiotensin-converting
    enzyme inhibitors (ACEI) and placebo (Time Frame week 0, 6, 12, 24).
    - Effect of dapagliflozin 10mg/d compared to placebo and dapagliflozin
    10mg +ACEI on proteinuria measured by quotient mg/g (Time Frame
    week 0, 6, 12 y 24).
    - Effect of dapagliflozin 10 mg/d compared to placebo and dapagliflozin
    10mg +ACEI on systolic/diastolic blood pressure (Time Frame: week 0,
    6, 12, 24).
    - Effect of dapagliflozin 10 mg/d compared to placebo and dapagliflozin
    10mg +ACEI on plasmatic levels of aldosterone, renin and angiotensin II
    hormones (Time Frame: week 0, 6, 12, 24).
    - Effect of dapagliflozin 10 mg/d compared to placebo and dapagliflozin
    10mg+ACEI on body weight and body mass index (Time Frame: week 0,
    6, 12, 24).
    - Effect of dapagliflozin 10mg/d compared to placebo and dapagliflozin
    10mg+ACEI on abdominal perimeter (Time Frame: week 0, 6, 12, 24).
    - Effect of dapagliflozin 10mg/d compared to placebo and dapagliflozin
    10mg+ACEI on hepatic esteatosis (Time Frame: week 0, 24).
    - Effect of dapagliflozin 10mg/d compared to placebo and dapagliflozin
    10mg+ACEI on glycated haemoglobin (HbA1c) (Time Frame: week 0, 12,
    24).
    - Effect of dapagliflozin 10mg/d compared to placebo and dapagliflozin
    10mg+ACEI on fasting glycemia (Time Frame: week 0, 6, 12, 24).
    - Effect of dapagliflozin 10mg/d compared to placebo and dapagliflozin
    10mg+ACEI on insulin resistance (Time Frame: week 0, 6, 12, 24).
    - Effect of dapagliflozin 10mg/d compared to placebo and dapagliflozin
    10mg+ACEI on seric uric acid (Time Frame: week 0, 6, 12, 24).
    - Effect of dapagliflozin 10 mg/d compared to placebo and dapagliflozin
    10mg+ACEI on selected neurohormones/ biomarkers (Time Frame:
    week 0, 12, 24).
    - Mantenimiento de la mejoría del estado de hiperfiltración glomerular
    hasta la semana 24 de tratamiento con dapagliflozina 10mg.
    - Comparación del efecto sobre la mTFG del tratamiento con
    dapagliflozina 10mg frente a IECAs+dapagliflozina y frente a placebo
    (intervalo semanas 0, 6, 12 y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en la proteinuria por cociente mg/g (intervalo semanas 0,
    6, 12 y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en la presión arterial (intervalo semanas 0, 6, 12 y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en los niveles de aldosterona, renina y angiotensina II
    (intervalo semanas 0, 6, 12 y 24).
    - Efecto de dapagliflozina 10mg/d comparado IECAs+dapagliflozina y
    con placebo en el peso e índice de masa corporal (IMC) (intervalo
    semana 0, 6, 12 y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en perímetro abdominal (intervalo semana 0, 6, 12 y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en esteatosis hepática (intervalo semana 0 y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en hemoglobina glicada (HbA1c) (intervalo semana 0, 12 y
    24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en glucemia en ayunas (intervalo semana 0, 6, 12, y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en resistencia a la insulina medidio por el índice de
    "homeostatic model assessment" (HOMA) (intervalo semana 0, 6, 12, y
    24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en ácido úrico sérico (intervalo semana 0, 6, 12 y 24).
    - Efecto de dapagliflozina 10mg/d comparado con IECAs+dapagliflozina
    y con placebo en biomarcadores urinarios seleccionados (intervalo
    semana 0 y 24).
    E.5.2.1Timepoint(s) of evaluation of this end point
    A follow up of 24 weeks.
    Seguimiento durante 24 semanas.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind Yes
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 40
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state60
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    No
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-12-28
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:45:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA